{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T13:52:21Z","timestamp":1782222741016,"version":"3.54.5"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,23]]},"DOI":"10.7759\/cureus.111357","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T13:20:31Z","timestamp":1782220831000},"source":"Crossref","is-referenced-by-count":0,"title":["Tofacitinib as Rescue Therapy in Steroid-Refractory Acute Severe Ulcerative Colitis: A Retrospective Cohort Study with Observations on Cytomegalovirus Coinfection"],"prefix":"10.7759","author":[{"given":"Subhadeep","family":"Banerjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawesh","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ujjwal","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunit","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag  K","family":"Tiwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinit M","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Singla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitesh K","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.386","article-title":"Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements","volume":"107","author":"Bitton A","year":"2012","unstructured":"Bitton A, Buie D, Enns R, et al.. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol. 2012, 107:179-94; author reply 195. 10.1038\/ajg.2011.386","journal-title":"Am J Gastroenterol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.2.4884.375","article-title":"Cortisone in ulcerative colitis; preliminary report on a therapeutic trial","volume":"2","author":"Truelove SC","year":"1954","unstructured":"Truelove SC, Witts LJ. Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. Br Med J. 1954, 2:375-8. 10.1136\/bmj.2.4884.375","journal-title":"Br Med J"},{"key":"ref3","article-title":"Response to first intravenous steroid therapy determines the subsequent risk of colectomy in ulcerative colitis patients","volume":"20","author":"Moln\u00e1r T","year":"2011","unstructured":"Moln\u00e1r T, Farkas K, Ny\u00e1ri T, Szepes Z, Nagy F, Wittmann T. Response to first intravenous steroid therapy determines the subsequent risk of colectomy in ulcerative colitis patients. J Gastrointestin Liver Dis. 2011, 20:359-63.","journal-title":"J Gastrointestin Liver Dis"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.crohns.2010.02.001","article-title":"The pattern and outcome of acute severe colitis","volume":"4","author":"Dinesen LC","year":"2010","unstructured":"Dinesen LC, Walsh AJ, Protic MN, et al.. The pattern and outcome of acute severe colitis. J Crohns Colitis. 2010, 4:431-7. 10.1016\/j.crohns.2010.02.001","journal-title":"J Crohns Colitis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15592","article-title":"Systematic review with meta-analysis: mortality in acute severe ulcerative colitis","volume":"51","author":"Dong C","year":"2020","unstructured":"Dong C, Metzger M, Holsb\u00f8 E, Perduca V, Carbonnel F. Systematic review with meta-analysis: mortality in acute severe ulcerative colitis. Aliment Pharmacol Ther. 2020, 51:8-33. 10.1111\/apt.15592","journal-title":"Aliment Pharmacol Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izad183","article-title":"Factors associated with response to rescue therapy in acute severe ulcerative colitis","volume":"30","author":"Li Wai Suen CF","year":"2024","unstructured":"Li Wai Suen CF, Seah D, Choy MC, De Cruz P. Factors associated with response to rescue therapy in acute severe ulcerative colitis. Inflamm Bowel Dis. 2024, 30:1389-405. 10.1093\/ibd\/izad183","journal-title":"Inflamm Bowel Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.04.016","article-title":"Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis","volume":"149","author":"Brandse JF","year":"2015","unstructured":"Brandse JF, van den Brink GR, Wildenberg ME, et al.. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology. 2015, 149:350-5.e2. 10.1053\/j.gastro.2015.04.016","journal-title":"Gastroenterology"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine T","year":"2022","unstructured":"Raine T, Bonovas S, Burisch J, et al.. ECCO guidelines on therapeutics in ulcerative colitis: medical treatment. J Crohns Colitis. 2022, 16:2-17. 10.1093\/ecco-jcc\/jjab178","journal-title":"J Crohns Colitis"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad004","article-title":"Rescue therapies for steroid-refractory acute severe ulcerative colitis: a review","volume":"17","author":"Gisbert JP","year":"2023","unstructured":"Gisbert JP, Garc\u00eda MJ, Chaparro M. Rescue therapies for steroid-refractory acute severe ulcerative colitis: a review. J Crohns Colitis. 2023, 17:972-94. 10.1093\/ecco-jcc\/jjad004","journal-title":"J Crohns Colitis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab052","article-title":"ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease","volume":"15","author":"Kucharzik T","year":"2021","unstructured":"Kucharzik T, Ellul P, Greuter T, et al.. ECCO guidelines on the prevention, diagnosis, and management of infections in inflammatory bowel disease. J Crohns Colitis. 2021, 15:879-913. 10.1093\/ecco-jcc\/jjab052","journal-title":"J Crohns Colitis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30873","article-title":"Steroid resistance\/dependence might be an alarming feature for cytomegalovirus infection among ulcerative colitis patients with increased disease activity","volume":"14","author":"Ger\u00e7eker E","year":"2022","unstructured":"Ger\u00e7eker E, Sayg\u0131l\u0131 F, Avc\u0131 A, Yuceyar H. Steroid resistance\/dependence might be an alarming feature for cytomegalovirus infection among ulcerative colitis patients with increased disease activity. Cureus. 2022, 14:e30873. 10.7759\/cureus.30873","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-013-0040-7","article-title":"The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders","volume":"27","author":"Furumoto Y","year":"2013","unstructured":"Furumoto Y, Gadina M. The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders. BioDrugs. 2013, 27:431-8. 10.1007\/s40259-013-0040-7","journal-title":"BioDrugs"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.11.022","article-title":"Efficacy of induction therapy with high-intensity tofacitinib in 4 patients with acute severe ulcerative colitis","volume":"17","author":"Berinstein JA","year":"2019","unstructured":"Berinstein JA, Steiner CA, Regal RE, et al.. Efficacy of induction therapy with high-intensity tofacitinib in 4 patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol. 2019, 17:988-990.e1. 10.1016\/j.cgh.2018.11.022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izab087","article-title":"Tofacitinib in acute severe ulcerative colitis: case series and a systematic review","volume":"27","author":"Jena A","year":"2021","unstructured":"Jena A, Mishra S, Sachan A, Singh H, Singh AK, Sharma V. Tofacitinib in acute severe ulcerative colitis: case series and a systematic review. Inflamm Bowel Dis. 2021, 27:e101-3. 10.1093\/ibd\/izab087","journal-title":"Inflamm Bowel Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45416","article-title":"Tofacitinib in steroid-refractory acute severe ulcerative colitis: a retrospective analysis","volume":"15","author":"Malakar S","year":"2023","unstructured":"Malakar S, Kothalkar S, Shamsul Hoda U, Ghoshal UC. Tofacitinib in steroid-refractory acute severe ulcerative colitis: a retrospective analysis. Cureus. 2023, 15:e45416. 10.7759\/cureus.45416","journal-title":"Cureus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa018","article-title":"Tofacitinib for rescue therapy in acute severe ulcerative colitis: a real-world experience","volume":"14","author":"Kotwani P","year":"2020","unstructured":"Kotwani P, Terdiman J, Lewin S. Tofacitinib for rescue therapy in acute severe ulcerative colitis: a real-world experience. J Crohns Colitis. 2020, 14:1026-8. 10.1093\/ecco-jcc\/jjaa018","journal-title":"J Crohns Colitis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2023.05.021","article-title":"The current role of Tofacitinib in acute severe ulcerative colitis in adult patients: A systematic review","volume":"55","author":"Mpakogiannis K","year":"2023","unstructured":"Mpakogiannis K, Fousekis FS, Christodoulou DK, Katsanos KH, Narula N. The current role of Tofacitinib in acute severe ulcerative colitis in adult patients: A systematic review. Dig Liver Dis. 2023, 55:1311-7. 10.1016\/j.dld.2023.05.021","journal-title":"Dig Liver Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad036","article-title":"Tofacitinib for acute severe ulcerative colitis: a systematic review","volume":"17","author":"Steenholdt C","year":"2023","unstructured":"Steenholdt C, Dige Ovesen P, Brynskov J, Seidelin JB. Tofacitinib for acute severe ulcerative colitis: a systematic review. J Crohns Colitis. 2023, 17:1354-63. 10.1093\/ecco-jcc\/jjad036","journal-title":"J Crohns Colitis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/apt.16463","article-title":"Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort","volume":"54","author":"Uzzan M","year":"2021","unstructured":"Uzzan M, Bresteau C, Laharie D, et al.. Tofacitinib as salvage therapy for 55 patients hospitalised with refractory severe ulcerative colitis: A GETAID cohort. Aliment Pharmacol Ther. 2021, 54:312-9. 10.1111\/apt.16463","journal-title":"Aliment Pharmacol Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002635","article-title":"Tofacitinib in acute severe ulcerative colitis (TACOS): a randomized controlled trial","volume":"119","author":"Singh A","year":"2024","unstructured":"Singh A, Goyal MK, Midha V, et al.. Tofacitinib in acute severe ulcerative colitis (TACOS): a randomized controlled trial. Am J Gastroenterol. 2024, 119:1365-72. 10.14309\/ajg.0000000000002635","journal-title":"Am J Gastroenterol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otaf013","article-title":"Tofacitinib for hospitalized acute severe ulcerative colitis management (The TRIUMPH Study)","volume":"7","author":"Narula N","year":"2025","unstructured":"Narula N, Pray C, Hamam H, et al.. Tofacitinib for hospitalized acute severe ulcerative colitis management (The TRIUMPH Study). Crohns Colitis 360. 2025, 7:otaf013. 10.1093\/crocol\/otaf013","journal-title":"Crohns Colitis 360"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13491","article-title":"Review article: the practical management of acute severe ulcerative colitis","volume":"43","author":"Seah D","year":"2016","unstructured":"Seah D, De Cruz P. Review article: the practical management of acute severe ulcerative colitis. Aliment Pharmacol Ther. 2016, 43:482-513. 10.1111\/apt.13491","journal-title":"Aliment Pharmacol Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1136\/gut.38.6.905","article-title":"Predicting outcome in severe ulcerative colitis","volume":"38","author":"Travis SP","year":"1996","unstructured":"Travis SP, Farrant JM, Ricketts C, et al.. Predicting outcome in severe ulcerative colitis. Gut. 1996, 38:905-910. 10.1136\/gut.38.6.905","journal-title":"Gut"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.4291\/wjgp.v5.i4.579","article-title":"Management of acute severe ulcerative colitis","volume":"5","author":"Kedia S","year":"2014","unstructured":"Kedia S, Ahuja V, Tandon R. Management of acute severe ulcerative colitis. World J Gastrointestin Pathophysiol. 2014, 5:579-588. 10.4291\/wjgp.v5.i4.579","journal-title":"World J Gastrointestin Pathophysiol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn WJ","year":"2017","unstructured":"Sandborn WJ, Su C, Sands BE, et al.. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017, 376:1723-36. 10.1056\/NEJMoa1606910","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.12.038","article-title":"A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis","volume":"132","author":"D'Haens G","year":"2007","unstructured":"D'Haens G, Sandborn WJ, Feagan BG, et al.. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology. 2007, 132:763-86. 10.1053\/j.gastro.2006.12.038","journal-title":"Gastroenterology"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.4103\/aca.ACA_157_18","article-title":"Descriptive statistics and normality tests for statistical data","volume":"22","author":"Mishra P","year":"2019","unstructured":"Mishra P, Pandey CM, Singh U, Gupta A, Sahu C, Keshri A. Descriptive statistics and normality tests for statistical data. Ann Card Anaesth. 2019, 22:67-72. 10.4103\/aca.ACA_157_18","journal-title":"Ann Card Anaesth"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318484","article-title":"British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults","volume":"68","author":"Lamb CA","year":"2019","unstructured":"Lamb CA, Kennedy NA, Raine T, et al.. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019, 68:s1-s106. 10.1136\/gutjnl-2019-318484","journal-title":"Gut"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjae100","article-title":"Rescue therapies for steroid-refractory acute severe ulcerative colitis: a systematic review and network meta-analysis","volume":"18","author":"Huang CW","year":"2024","unstructured":"Huang CW, Yen HH, Chen YY. Rescue therapies for steroid-refractory acute severe ulcerative colitis: a systematic review and network meta-analysis. J Crohns Colitis. 2024, 18:2063-2075. 10.1093\/ecco-jcc\/jjae100","journal-title":"J Crohns Colitis"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2010.10.031","article-title":"Human cytomegalovirus immunity and immune evasion","volume":"157","author":"Jackson SE","year":"2011","unstructured":"Jackson SE, Mason GM, Wills MR. Human cytomegalovirus immunity and immune evasion. Virus Res. 2011, 157:151-60. 10.1016\/j.virusres.2010.10.031","journal-title":"Virus Res"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/493872-tofacitinib-as-rescue-therapy-in-steroid-refractory-acute-severe-ulcerative-colitis-a-retrospective-cohort-study-with-observations-on-cytomegalovirus-coinfection","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T13:20:32Z","timestamp":1782220832000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/493872-tofacitinib-as-rescue-therapy-in-steroid-refractory-acute-severe-ulcerative-colitis-a-retrospective-cohort-study-with-observations-on-cytomegalovirus-coinfection"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.111357","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,23]]}}}